Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2016 Jan;14(1):71-9. doi: 10.1016/j.cgh.2015.04.180. Epub 2015 May 5.

Features of Patients With Crohn's Disease and Hidradenitis Suppurativa.

Author information

1
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
2
Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
3
Department of Dermatology, Hopital Huriez, CHU Lille, Lille, France.
4
Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.

Abstract

BACKGROUND & AIMS:

There have been reports of an association between Crohn's disease and hidradenitis suppurativa, a chronic, relapsing, inflammatory condition of the skin. We investigated features of hidradenitis suppurativa in patients with Crohn's disease by analyzing clinical data and performing a literature review.

METHODS:

We performed a retrospective study by using information from the Mount Sinai Medical Center database from 2003 through 2013; International Classification of Diseases, 9th Revision codes were used to identify patients who had both Crohn's disease and hidradenitis suppurativa. We identified a total of 18 patients with inflammatory bowel disease (15 with Crohn's disease, 3 with ulcerative colitis) and hidradenitis suppurativa. We also performed a systematic search for publications listed in PubMed through December 2013.

RESULTS:

We identified 15 patients with Crohn's disease and hidradenitis suppurativa who met the inclusion criteria (11 women, 4 men). Nine patients were black, 5 were white, and 1 was Asian. Regions most affected by hidradenitis suppurativa included the axilla (53%), inguinal region (47%), and perianal region (73%). Seven patients had colonic Crohn's disease, and 8 had ileocolonic Crohn's disease; 10 patients had perianal disease. Fourteen patients received medical treatment for hidradenitis suppurativa and for Crohn's disease. Twelve patients were treated with tumor necrosis factor inhibitors for Crohn's disease (11 received infliximab and 4 received adalimumab). Nine patients required dose escalation; 11 responded to tumor necrosis factor inhibitors, and 8 required surgery. Four patients were treated with tumor necrosis factor inhibitors for hidradenitis suppurativa (all with infliximab). Three required a dose escalation; 4 responded to tumor necrosis factor inhibitors, and 3 required surgery.

CONCLUSIONS:

Crohn's disease and hidradenitis suppurativa are severe inflammatory conditions that can develop in the same patient. They frequently require increased medical and surgical therapy.

KEYWORDS:

Anti-TNF; Autoimmune; Inflammation; Inflammatory Bowel Disease

Comment in

PMID:
25956836
DOI:
10.1016/j.cgh.2015.04.180
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center